scholarly journals Urinary podocin level as a predictor of diabetic kidney disease

2018 ◽  
Vol 8 (3) ◽  
pp. 26-26
Author(s):  
Abdelbassit ElShaarawy ◽  
Maha Abdelmoneim Behairy ◽  
Somia Abdelhameed Bawady ◽  
Hoda Ahmed Abdelsattar ◽  
Eman Shadad
Keyword(s):  
Kidney Disease ◽  
Serum Creatinine ◽  
Diabetic Kidney Disease ◽  
Fasting Blood Glucose ◽  
University Hospital ◽  
Control Group ◽  
High Morbidity ◽  
Diabetic Kidney ◽  
Type 2 Dm

Background: Albuminuria showed to be a deteriorating condition in diabetic kidney disease (DKD) associated with high morbidity and mortality. A need for a novel marker for early detection of DKD development and progression becomes mandating. Objective: To study the clinical value of urinary podocin as an early marker of diabetic kidney disease and its association with severity of the disease. Patients and Methods: This study included 45 individuals with type 2 DM whose GFR >60 mL/min/1.73 m2 , recruited from Ain Shams University Hospital, Cairo, Egypt. Patients were further divided into three groups according to urinary albumin/creatinine ratio (ACR). In addition to, ten healthy volunteers serving as the control group was enrolled in the study. Routine chemistry including serum creatinine, fasting blood glucose (FBG), HbA1c, albumin, lipid profile, urine analysis, ACR and urinary podocin quantification were conducted for all participants (by ELISA method). Results: Podocin was higher in patients with ACR <30 mg/g, ACR 30-299 mg/g and ACR ≥ 300 mg/g versus healthy controls, respectively (P<0.001). Both GFR and serum albumin showed highly significant negative correlations with urinary podocin. Significant positive correlations were detected between urinary podocin with blood urea nitrogen (BUN), serum creatinine, FBG, HbA1c, cholesterol, and triglyceride levels. Conclusions: Urinary podocin is assumed to be a promising marker for early DKD detection in type 2 DM patients.

scholarly journals Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Randa I. Farah ◽  
Mohammed Q. Al-Sabbagh ◽  
Munther S. Momani ◽  
Asma Albtoosh ◽  
Majd Arabiat ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Laboratory Data ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Diabetic Kidney ◽  
Type 2 Dm

Abstract Aim Diabetic kidney disease (DKD) is a major long-term complication of diabetes mellitus (DM). Given the paucity of data on DKD in Jordan, we aimed to evaluate the prevalence, characteristics and correlates of DKD in Jordanian patients with type 2 DM. Methods This cross-sectional study included 1398 adult patients with type 2 DM who sought medical advice in the endocrinology clinic between March and September 2019. Demographic, clinical and laboratory data were reviewed. DKD was defined as reduced eGFR, and/or albuminuria. Three regression models were constructed to identify factors associated with CKD stages, albuminuria and DKD. Results Overall, 701 (50.14%) patients had DKD, with a median age of 59.71 ± 11.36  years. Older age, high triglycerides, and low high-density lipoprotein were associated with DKD (multivariable odds ratio [OR]: 1.02, 95% confidence interval [CI]: 1.01–1.03, p < 0.01; OR: 1.1, 95% CI: 1.01–1.2; and OR: 0.98, 95% CI: 0.97–0.99, p < 0.01 respectively). Metformin and renin-angiotensin system blockers were negatively associated with albuminuria and chronic kidney disease stages (p < 0.01). Conclusion Our study demonstrated that approximately one half of patients with type 2 DM had DKD. Further studies are necessary to understand this high prevalence and the underlying factors. Future research are needed to assess implementing targeted community-based intervention.

scholarly journals Prevalence and characteristics of diabetic kidney disease in type 2 diabetic patients in Abidjan, Côte d’Ivoire

2018 ◽  
Vol 7 (2) ◽  
pp. 98-103
Author(s):  
Sindou Sanogo ◽  
Serge Didier Konan ◽  
Kouamé Hubert Yao ◽  
Emma Kouassi ◽  
Séry Patrick Diopoh ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Associated Factors ◽  
Diabetic Kidney Disease ◽  
University Hospital ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Cross Sectional ◽  
Diabetic Kidney ◽  
Type 2 Diabetic

Introduction: Diabetes mellitus is a disease whose prevalence has been steadily increasing worldwide. Objectives: To evaluate the prevalence of diabetic kidney disease and to identify the associated factors in type 2 diabetic patients. Material and Methods: This was a descriptive and analytical cross-sectional study. The study was conducted over a period from January to June 2016, among patients with type 2 diabetes, followed up at the Division of Diabetology of the University Hospital of Treichville, Abidjan. Results: Of 154 included patients, diabetic nephropathy (DN) was observed in 40 cases (25.9% prevalence). We observed a female predominance (sex ratio; 0.17) and the mean age of 57.7 ± 11 years. Based on the K/DOQI guidelines, half of our patients had stage 3 kidney disease. Complications such as diabetic retinopathy (100%), hypertension (HT) (75%), dyslipidemia (45%) and obesity (30%) were found. Factors such as female sex (P = 0.001; OR [95% CI] = 4.76 [1.85-12.19]), a range 55-65 years old (P = 0.010; OR [95% CI] = 2.64 [1.26-5.53]), obesity (P = 0.012; OR [95% CI] = 3.06 [1.27-7.36]), hypertension (P = 0.0001; OR [95% CI] = 4.77 [2.12-10.71]) and HbA1c <7% (P = 0.002; OR [94% CI] = 3.42 [1.57-7.44]) were associated with nephropathy by multivariate analysis. Conclusion: the prevalence of diabetic kidney disease is high in our study. The associated factors are non-modifiable such as female gender and age, but also modifiable such as obesity and hypertension.

scholarly journals Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Agnieszka Gala-Błądzińska ◽  
Paulina Dumnicka ◽  
Beata Kuśnierz-Cabala ◽  
Katarzyna Rybak ◽  
Ryszard Drożdż ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Early Stage ◽  
Control Group ◽  
Tubular Damage ◽  
Diabetic Kidney ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase

Background. Two clinical phenotypes of diabetic kidney disease (DKD) have been reported, that is, with or without increased albuminuria. The aim of study was to assess the usefulness of urinary neutrophil gelatinase-associated lipocalin (uNGAL) for the early diagnosis of DKD in the type 2 diabetes mellitus (T2DM). Methods. The study group consisted of 123 patients with T2DM (mean age 62 ± 14 years), with urine albumin/creatinine ratio (uACR) < 300 mg/g and eGFR ≥ 60 ml/min/1.73 m2. The control group included 22 nondiabetic patients with comparable age, sex, and comorbidities. uNGAL, albumin, and creatinine were measured in the first morning urine samples. uACR and uNGAL/creatinine ratios (uNCR) were calculated. Results. In the control group, maximum uNCR was 39.64 µg/g. In T2DM group, 24 patients (20%) had higher results, with the maximum value of 378.6 µg/g. Among patients with uNCR > 39.64 µg/g, 13 (54%) did not have markedly increased albuminuria. Women with T2DM had higher uNCR than men (p<0.001), without difference in uACR (p=0.09). uNCR in T2DM patients correlated significantly with HbA1c. Sex, total cholesterol, and uACR were independent predictors of uNCR above 39.64 µg/g. Conclusions. Increased uNGAL and uNCR may indicate early tubular damage, associated with dyslipidemia and worse diabetes control, especially in females with T2DM.

Interleukins and miRNAs intervene in the early stages of diabetic kidney disease in Type 2 diabetes mellitus patients

2019 ◽  
Vol 13 (18) ◽  
pp. 1577-1588 ◽  
Author(s):  
Ligia Petrica ◽  
Oana Milas ◽  
Mihaela Vlad ◽  
Adrian Vlad ◽  
Florica Gadalean ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Case Series ◽  
Diabetic Kidney ◽  
Type 2 Dm ◽  
Case Series Study

Aim: The involvement of proinflammatory interleukins (IL) in diabetic kidney disease of Type 2 diabetes mellitus (DM) patients was studied in relation to a particular miRNA profile. Materials & methods: A total of 117 patients with Type 2 DM and 11 controls were enrolled in a case series study. Serum and urinary ILs and miRNAs were assessed. Results: IL-1α correlated with miRNA21, 124, estimated glomerular filtration rate (eGFR) and negatively with miRNA125a and 192; IL-8 with miRNA21, 124, eGFR and negatively with miRNA125a, 126 and 146a; IL-18 with miRNA21, 124 and negatively with miRNA146a, 192, eGFR. Conclusion: There is an association between specific serum and urinary ILs and serum and urinary miRNAs profiles in the inflammatory response in Type 2 DM patients with diabetic kidney disease.

scholarly journals Fetuin-A gene polymorphism and its serum level association with atherosclerotic vascular disease in type 2 diabetes patients with early diabetic kidney disease

2020 ◽  
Vol 7 (11) ◽  
pp. 4122-4131
Author(s):  
Eman Y. Morsy ◽  
Neveen L. Saad ◽  
Hesham A. Elghoneimy ◽  
Abd Alhalim G. Smeid ◽  
Azza A. Ismail
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Control Group ◽  
Atherosclerotic Vascular Disease ◽  
Fetuin A ◽  
Diabetic Kidney ◽  
Increased Risk

Background: The incidence of type 2 diabetes mellitus (T2DM) is increasing over the past years. Early identification and management of its complications, especially diabetic kidney disease (DKD), is of great importance. Multiple factors play a role in the pathogenesis of T2DM and DKD. We aimed to study Fetuin-A gene polymorphisms and Fetuin-A serum levels in T2DM patients with early DKD. Methods: The present work was conducted on 120 patients with T2DM (60 patients with microalbuminuria and 60 without albuminuria), and 30 healthy subjects (as a control group). Serum Fetuin-A levels were measured with ELISA. Fetuin-A, Thr256Ser and Thr248Met polymorphisms were determined by PCR-RFLP. Results: Patients with T2DM had a significantly higher mean serum Fetuin-A compared to controls (p < 0.001), while no difference was observed when comparing mean serum Fetuin-A in patients with microalbuminuria and patients without albuminuria (p = 0.916). Multivariate regression analysis demonstrated that carotid intima-media thickness (CIMT) and insulin resistance had positive correlations with serum Fetuin-A (p < 0.001 and p < 0.001, respectively). Ankle-brachial pressure index (ABPI) had a negative correlation with serum Fetuin-A (p=0.046), while Fetuin-A levels neither affected eGFR nor albuminuria. The distribution of the alleles of both polymorphisms showed increased frequency of TT (rs248) and GG (rs256) in patients without albuminuria compared to patients with microalbuminuria. Conclusion: Increased serum Fetuin-A is associated with insulin resistance and increased risk of atherosclerosis in patients with T2DM, but is not associated with the development of DKD. TT (rs248) and GG (rs256) polymorphisms may be associated with lower risk of DKD.

scholarly journals The effect of Astaxanthin on Experimentally Induced Diabetic Kidney Disease

2021 ◽  
pp. 98-112
Author(s):  
Yusra Saleh Andijani ◽  
Huda Mohammed Alkreathy ◽  
Ahmed Esmat
Keyword(s):  
Blood Glucose ◽  
Kidney Disease ◽  
Serum Creatinine ◽  
Diabetic Kidney Disease ◽  
Fasting Blood Glucose ◽  
Diabetic Rats ◽  
Kidney Damage ◽  
Oral Gavage ◽  
Duration Of Treatment ◽  
Diabetic Kidney

Aim: To identify the potential renal protective effect produced by astaxanthin on streptozotocin-produced diabetic kidney disease in rats. Study Design: Male Wistar rats (n=60) were separated into six groups, control, diabetic (streptozotocin 45 mg/kg single intraperitoneal injection), diabetic + ramipril (1 mg/kg oral gavage), diabetic + astaxanthin (10mg/kg oral gavage), diabetic + astaxanthin (50 mg/kg oral gavage), and astaxanthin-alone (50 mg/kg oral gavage) group. Place and Duration of Treatment: Department of Pharmacology, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Duration of treatment was eight weeks. Methodology: Fasting blood glucose, and symptoms of diabetes were evaluated weekly. Kidneys were evaluated by measuring serum creatinine level, kidney index, and hematoxylin and eosin staining. Results: Eight-week astaxanthin treatment (50 mg/kg) in streptozotocin-produced diabetic kidney disease in rats significantly alleviated the diabetic symptoms (p = 0.05), and the decrease in body weight (P = .05) compared to nontreated diabetic rats. Nonetheless, the same dose produced a nonsignificant decline in fasting blood glucose level contrasted to diabetic rats (P = .45). Kidney index and serum creatinine of diabetic rats were significantly attenuated by both 10 and 50 mg/kg astaxanthin doses (P = .05). Additionally, renal architecture was preserved by high-dose astaxanthin treatment compared to nontreated diabetic rats. Conclusion: Astaxanthin could protect against kidney damage associated with diabetes. Nevertheless, the impact of astaxanthin on biological markers of kidney damage in diabetes and the molecular pathways implicated in diabetic kidney disease requires additional investigation.

scholarly journals Clinical Efficacy and Safety of Yi-Shen-Hua-Shi Granule for Diabetic Kidney Disease: A Cohort Study

2020 ◽  
Author(s):  
Yebei Li ◽  
Zhipeng Yan ◽  
Kang Wang ◽  
Tianlun Huang ◽  
Xin Liu ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Adverse Reactions ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Control Group ◽  
Efficacy And Safety ◽  
Diabetic Kidney

Abstract Background: The present study aims to explore the relative efficacy and safety of Yi-Shen-Hua-Shi (YSHS) granule in diabetic kidney disease (DKD) patients. Methods: A total of 260 DKD patients with the urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g and estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m2 were included. 130 patients receiving YSHS plus irbesartan and 130 patients with irbesartan alone. The primary outcomes were included serum creatinine (Scr), 24-hour urinary protein (24h UTP), UACR, and the overall response rate (ORR). The secondary outcomes included fasting blood glucose (FBG), hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL-C). Results: At the end of 12 weeks, compared with the controls, the YSHS group could effectively improve the level of 24h UTP (P = 0.007), UACR (P = 0.001), FBG (P = 0.024), HbA1c (P = 0.005), TC (P = 0.018), TG (P = 0.001), and LDL-C (P = 0.034). The ORR in the YSHS group and control group was 47 % versus 30 % at 12 weeks (P = 0.005), respectively. There was no statistical difference in major adverse reactions between the two groups during treatment.Conclusions: The YSHS granule has significant curative effects on DKD, especially in reducing proteinuria, improving blood glucose and lipid metabolism, with no obvious adverse reactions.

scholarly journals Urinary Microvesicle-Bound Uromodulin: A Potential Molecular Biomarker in Diabetic Kidney Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Neng-jun Lou ◽  
Yi-hong Ni ◽  
Hong-ying Jia ◽  
Jing-ti Deng ◽  
Lu Jiang ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Linear Regression Analysis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Specific Marker ◽  
Stepwise Linear Regression Analysis ◽  
Diabetic Kidney ◽  
Independent Determinant

This study was designed to investigate the changes of urinary microvesicle-bound uromodulin and total urinary uromodulin levels in human urine and the correlations with the severity of diabetic kidney disease (DKD). 31 healthy subjects without diabetes and 100 patients with type 2 diabetes mellitus (T2DM) were included in this study. The patients with T2DM were divided into three groups based on the urinary albumin/creatinine ratio (UACR): normoalbuminuria group (DM, n=46); microalbuminuria group (DN1, n=32); and macroalbuminuria group (DN2, n=22). We use a specific monoclonal antibody AD-1 to capture the urinary microvesicles. Urinary microvesicle-bound uromodulin and total urinary uromodulin levels were determined by enzyme-linked immunosorbent assay (ELISA). Our results showed that the levels of urinary microvesicle-bound uromodulin in DN1 and DN2 groups were significantly higher than those in control group and DM group (P<0.01). Multiple stepwise linear regression analysis showed that UACR was independent determinant for urinary microvesicle-bound uromodulin (P<0.05) but not for total urinary uromodulin. These findings suggest that the levels of urinary microvesicle-bound uromodulin are associated with the severity of DKD. The uromodulin in urinary microvesicles may be a specific marker of DKD and potentially may be used to predict the onset and/or monitor the progression of DKD.

scholarly journals Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease

2020 ◽  
Vol 51 (10) ◽  
pp. 806-814 ◽  
Author(s):  
Xiangyu Wang ◽  
Huijie Zhang ◽  
Qian Zhang ◽  
Meiping Guan ◽  
Shuyue Sheng ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Insulin Glargine ◽  
Diabetic Kidney Disease ◽  
Intervention Group ◽  
Percentage Change ◽  
Control Group ◽  
Diabetic Kidney ◽  
Renal Outcomes

<b><i>Background:</i></b> Cardiovascular outcomes in clinical trials with type 2 diabetes mellitus (T2DM) patients have shown that glucagon-like peptide-1 receptor agonist can have a beneficial effect on the kidney. This trial aimed to assess the effects of exenatide on renal outcomes in patients with T2DM and diabetic kidney disease (DKD). <b><i>Methods:</i></b> We performed a randomized parallel study encompassing 4 general hospitals. T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m<sup>2</sup> and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) &#x3e;0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine (control group) for 24 weeks. The primary outcome was the UAER percentage change from the baseline after 24 weeks of intervention. The rates of hypoglycemia, adverse events (AEs), and change in eGFR during the follow-up were measured as safety outcomes. <b><i>Results:</i></b> Between March 2016 and April 2019, 92 patients were randomized and took at least 1 dose of the study drug. The mean age of the participants was 56 years. At baseline, the median UAER was 1,512.0 mg/24 h and mean eGFR was 70.4 mL/min/1.73 m<sup>2</sup>. After 24 weeks of treatment, the UAER percentage change was significantly lower in the intervention group than in the control group (<i>p</i> = 0.0255). Moreover, the body weight declined by 1.3 kg in the intervention group (the difference between the 2 groups was 2.7 kg, <i>p</i> = 0.0001). Compared to the control group, a lower frequency of hypoglycemia and more gastrointestinal AEs were observed in the intervention group. <b><i>Conclusion:</i></b> Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD.

Albuminuria Is More Closely Associated with Vascular Endothelial Function than eGFR in Type 2 Diabetes with Diabetic Kidney Disease

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 443-P
Author(s):  
YOSHINORI KAKUTANI ◽  
MASANORI EMOTO ◽  
YUKO YAMAZAKI ◽  
KOKA MOTOYAMA ◽  
TOMOAKI MORIOKA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Endothelial Function ◽  
Diabetic Kidney Disease ◽  
Vascular Endothelial ◽  
Vascular Endothelial Function ◽  
Diabetic Kidney
Sign in / Sign up

Export Citation Format

Share Document